A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
THIEBAUT, Rodolphe
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
< Réduire
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Langue
EN
Article de revue
Ce document a été publié dans
Cell Reports Medicine. 2024-03-19, vol. 5, n° 3, p. 101467
Résumé en anglais
Nipah virus (NiV) has been recently ranked by the World Health Organization as being among the top eight emerging pathogens likely to cause major epidemics, whereas no therapeutics or vaccines have yet been approved. We ...Lire la suite >
Nipah virus (NiV) has been recently ranked by the World Health Organization as being among the top eight emerging pathogens likely to cause major epidemics, whereas no therapeutics or vaccines have yet been approved. We report a method to deliver immunogenic epitopes from NiV through the targeting of the CD40 receptor of antigen-presenting cells by fusing a selected humanized anti-CD40 monoclonal antibody to the Nipah glycoprotein with conserved NiV fusion and nucleocapsid peptides. In the African green monkey model, CD40.NiV induces specific immunoglobulin A (IgA) and IgG as well as cross-neutralizing responses against circulating NiV strains and Hendra virus and T cell responses. Challenge experiments using a NiV-B strain demonstrate the high protective efficacy of the vaccine, with all vaccinated animals surviving and showing no significant clinical signs or virus replication, suggesting that the CD40.NiV vaccine conferred sterilizing immunity. Overall, results obtained with the CD40.NiV vaccine are highly promising in terms of the breadth and efficacy against NiV.< Réduire
Mots clés en anglais
CD40-targeting vaccine
Henipavirus
Nipah virus
cross-neutralizing responses
Dendritic cell-based vaccine
Epitope mapping
Germinal center reaction
Neutralizing antibodies
Prophylactic vaccine
Sterilizing immunity
Project ANR
Initiative for the creation of a Vaccine Research Institute - ANR-10-LABX-0077
Unités de recherche